Rating Change #1
has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Highlights from the ratings report include:
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Life Sciences Tools & Services industry. The net income increased by 69.7% when compared to the same quarter one year prior, rising from -$0.89 million to -$0.27 million.
- Despite its growing revenue, the company underperformed as compared with the industry average of 8.0%. Since the same quarter one year prior, revenues slightly increased by 1.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- The gross profit margin for NORDION INC is rather high; currently it is at 51.80%. Regardless of NDZ's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, NDZ's net profit margin of -0.50% significantly underperformed when compared to the industry average.
- NDZ's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 34.32%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, NORDION INC's return on equity significantly trails that of both the industry average and the S&P 500.
Nordion Inc. provides products and services for the prevention, diagnosis, and treatment of diseases worldwide. The company's Targeted Therapies segment offers TheraSphere, a therapeutic medical device used in the treatment of inoperable primary and metastatic liver cancer. Nordion has a market cap of $409.2 million and is part of the health care sector and health services industry. Shares are up 4.2% year to date as of the close of trading on Wednesday.
You can view the full
Nordion Ratings Report
or get investment ideas from our
investment research center
-- Reported by Kevin Baker in Palm Beach Gardens, Fla.
check out our Ratings Research Center.
For all other upgrades and downgrades made by TheStreet Ratings Model today check out our
upgrades and downgrades list
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.